Faroongsarng Damrongsak
Drug Delivery System Excellent Center, Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, 90112, Thailand.
AAPS PharmSciTech. 2016 Apr;17(2):474-81. doi: 10.1208/s12249-015-0372-3. Epub 2015 Aug 6.
Drug-protein binding may play a role in the thermal energetics of protein denaturation and could lead to the determination of its equilibrium dissociation parameter. The aim of this study was to assess the energetics of a drug that was bound to human serum albumin (HSA) during thermal denaturation. Drugs that were bound at a single high-affinity primary binding site on HSA, including diazepam and ibuprofen, were employed. Commercial HSA was treated with charcoal to remove stabilizers and adjusted to 20% w/v in a pH 7.4 buffered solution. Serial concentrations of individual drugs up to 0.16 mmole/g-protein were added to the cleaned HSA solutions whereas diazepam was added to a commercial HSA solution. Samples were subjected to differential scanning calorimetry (DSC) set to run from 37 to 90°C at 3.0°C/min. Binding of the drug slightly increased the denaturing temperature of the cleaned HSA due to a shift in the equilibrium toward the native protein bound with the drug. Diazepam depressed the denaturing temperature of the commercial HSA by competing with the stabilizers already bound to the primary site of the HSA. This yielded not only the HSA-stabilizer but also the HSA-diazepam type complexes that exhibited a different denaturation process. A rational approximation of the Lumry-Eyring protein denaturation model was used to treat the DSC endotherms. The approximated scheme: [Formula: see text] was successfully fitted to the data. It was used to determine the dissociation parameters for diazepam and ibuprofen bound to the HSA. These results were comparable to those obtained from other methods.
药物与蛋白质的结合可能在蛋白质变性的热动力学中发挥作用,并可能导致其平衡解离参数的测定。本研究的目的是评估一种在热变性过程中与人类血清白蛋白(HSA)结合的药物的能量学。使用了在HSA上单个高亲和力主要结合位点结合的药物,包括地西泮和布洛芬。将商业HSA用活性炭处理以去除稳定剂,并在pH 7.4缓冲溶液中调节至20% w/v。将高达0.16毫摩尔/克蛋白质的单个药物系列浓度添加到纯化的HSA溶液中,而地西泮则添加到商业HSA溶液中。样品进行差示扫描量热法(DSC),设置为在3.0°C/分钟的速率下从37°C运行至90°C。药物的结合由于平衡向与药物结合的天然蛋白质转移而略微提高了纯化HSA的变性温度。地西泮通过与已经结合到HSA主要位点的稳定剂竞争而降低了商业HSA的变性温度。这不仅产生了HSA-稳定剂复合物,还产生了表现出不同变性过程的HSA-地西泮复合物。使用Lumry-Eyring蛋白质变性模型的合理近似来处理DSC吸热曲线。近似方案:[公式:见文本]成功拟合数据。它被用于确定与HSA结合的地西泮和布洛芬的解离参数。这些结果与通过其他方法获得的结果相当。